RecruitingPhase 3NCT05819866
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
Studying Leukodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Minoryx Therapeutics, S.L.
- Intervention
- Leriglitazone(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2023 – 2027
Study locations (13)
- Stanford University Medical Center, Palo Alto, California, United States
- Neuro Medicine Hospital / UF Health, Gainesville, Florida, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Minnesota, Minneota, Minnesota, United States
- Health University of Utah, Salt Lake City, Utah, United States
- Hospital Austral, Buenos Aires, Argentina
- Federal University of Sao Paulo, São Paulo, Brazil
- ICM La Pitie Salpetriere, Paris, France
- Klinik und Poliklinik für Neurologie-Leipzig, Leipzig, Germany
- Sir Ganga Ram Hospital, New Delhi, India
- Hospital 12 de Octubre, Madrid, Spain
- National Hospital for Neurology and Neurosurgery, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05819866 on ClinicalTrials.govOther trials for Leukodystrophy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07222371An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related LeukodystrophyUniversity of California, San Diego
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06369974Single Participant Study of an Experimental ASO Treatment for TUBB4A-related LeukodystrophyMassachusetts General Hospital
- RECRUITINGNANCT06224413A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene AutotemcelGenetix Biotherapeutics Inc.
- RECRUITINGPHASE1, PHASE2NCT05757141An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter DiseaseCalico Life Sciences LLC
- RECRUITINGNANCT03047369The Myelin Disorders Biorepository ProjectChildren's Hospital of Philadelphia
- RECRUITINGPHASE1NCT02254863UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like CellsJoanne Kurtzberg, MD
- RECRUITINGNCT03639285Natural History, Diagnosis, and Outcomes for LeukodystrophiesUniversity of Utah